Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease
- Conditions
- Peyronie's Disease
- Registration Number
- NCT05873595
- Lead Sponsor
- Endo Pharmaceuticals
- Brief Summary
This is an observational study, meaning participants will not receive any investigational treatment as part of this study.
Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of Peyronie's Disease (PD) to evaluate the management of PD.
- Detailed Description
Each participant of the study will have their data collected from the date of confirmed diagnosis of PD to the date of enrollment in the registry, post consent. Data will be collected from the participant's clinical records as well as from the participant directly. Data will be collected through Pulse Infoframe's technology platform.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 29
- Any adult with a confirmed clinical diagnosis of PD.
- Age 18 years (or age of majority in their jurisdiction) or older at time of enrollment.
- Willing to participate in the registry (including completion of ePROs) and complete the informed consent form.
- Having received PD treatment within 2 weeks before enrollment, at enrollment or any time after the date of enrollment. After a confirmed diagnosis of PD, not having received PD treatment.
- Able to participate in English based registry.
Key Exclusion criteria:
- Not having a clinical diagnosis of PD.
- Age less than 18 years.
- Do not provide informed consent.
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants Receiving Each Treatment Type for PD Up to 12 months
- Secondary Outcome Measures
Name Time Method Participant Satisfaction Questionnaire Up to 12 months Number of Participants Receiving Post-Procedural Care by the Treating Physician Up to 12 months Change from Baseline in Peyronie's Disease Questionnaire (PDQ) Score Up to 12 months Change from Baseline in International Index of Erectile Function (IIEF) Score Up to 12 months Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score Up to 12 months Change from Baseline in Beck Anxiety Inventory (BAI) Scale Score Up to 12 months
Trial Locations
- Locations (7)
Endo Pharmaceuticals Clinical Site 3
🇺🇸Miami, Florida, United States
Endo Pharmaceuticals Clinical Site 4
🇺🇸Houston, Texas, United States
Endo Pharmaceuticals Clinical Site 6
🇺🇸Greenwood, Indiana, United States
Endo Pharmaceuticals Clinical Site 7
🇺🇸Gahanna, Ohio, United States
Endo Pharmaceuticals Clinical Site 1
🇺🇸Orem, Utah, United States
Endo Pharmaceuticals Clinical Site 5
🇺🇸Lansing, Michigan, United States
Endo Pharmaceuticals Clinical Site 2
🇺🇸San Diego, California, United States